Is papillary thyroid cancer curable?

Often, yes. The American Thyroid Association says thyroid cancer is often cured by surgery alone, especially when the cancer is small. Some people also get radioactive iodine. Your care team will tell you what cure means for your case and how they will check for any return.

Can papillary thyroid cancer come back years later?

Yes. The NCI says thyroid cancer can come back after treatment, in the neck or in other parts of the body. That is why follow-up visits, blood tests, and neck ultrasounds continue for years. The ATA says the chance of recurrence is higher in people 55 or older and with larger or more aggressive tumors.

Does spread to the lymph nodes lower survival much?

For papillary cancer, not by much. The American Cancer Society lists 99% 5-year relative survival for regional spread, compared with more than 99% for localized cancer. Lymph node spread can raise the chance of recurrence and change treatment plans.

Why is my papillary cancer stage I if it spread to lymph nodes?

Under the AJCC 8th edition, everyone younger than 55 has stage I disease unless the cancer has spread to distant sites. Lymph node spread alone does not raise the stage in that age group. Age is built into the staging because it strongly affects outlook.

Are thyroid cancer survival rates improving?

SEER data show 5-year relative survival for all thyroid cancers rose from about 93% in the mid-1970s to about 98% in recent years. The American Cancer Society notes that people diagnosed today may do better than published rates, because those rates are based on people treated at least 5 years earlier.

What Is the Survival Rate for Papillary Thyroid Cancer?

The short answer: Papillary thyroid cancer has one of the best outlooks of any cancer. American Cancer Society figures, drawn from NCI SEER data for people diagnosed from 2015 to 2021, put 5-year relative survival above 99% for all stages combined. It is 99% with regional spread and 71% after spread to distant organs.

This article explains where those numbers come from, what they leave out, and how to match them to your own pathology report. It does not replace a talk with your cancer care team.

What is the 5-year survival rate for papillary thyroid cancer by stage?

The American Cancer Society survival page (last revised June 30, 2025) splits papillary thyroid cancer out from the other thyroid cancer types. Its numbers come from SEER*Explorer and cover people diagnosed between 2015 and 2021:

Localized (no sign of spread outside the thyroid): more than 99%
Regional (spread to nearby structures or lymph nodes): 99%
Distant (spread to far parts of the body, such as the lungs): 71%
All SEER stages combined: more than 99%

For comparison, the same page lists 98% overall for follicular cancer, 93% for medullary cancer, and 10% for anaplastic cancer. The type of thyroid cancer matters as much as the stage. That is why a "thyroid cancer" number you read elsewhere may not fit a papillary diagnosis.

What does a "5-year relative survival rate" actually mean?

A relative survival rate compares people who have the cancer with people of the same age who do not. The American Cancer Society gives this example: a 90% rate means people with that cancer are about 90% as likely as people without it to live at least 5 years after diagnosis.

So "more than 99%" does not mean 1 in 100 people dies at the 5-year mark. It means papillary thyroid cancer, as a group, removes very little from expected survival over 5 years. NCI SEER adds that relative survival excludes the risk of dying from other causes. SEER also says these statistics come from large groups and cannot predict exactly what will happen to one person.

How do the NCI SEER numbers for all thyroid cancers compare?

The NCI SEER Cancer Stat Facts page for thyroid cancer reports newer data, but it groups all thyroid cancer types together. Papillary, follicular, medullary, and anaplastic cancers all count in these figures. Based on SEER 21 (excluding Illinois) for 2016 to 2022:

Overall 5-year relative survival: 98.3%
Localized: 99.9% (63% of cases are found at this stage)
Regional: 98.1% (31% of cases)
Distant: 48.3% (3% of cases)
Unknown or unstaged: 91.9% (3% of cases)

The distant-stage figure of 48.3% is much lower than the 71% papillary-only figure. Anaplastic cancer is rare but very aggressive, and it pulls the combined number down. Papillary cancer makes up about 70% to 80% of all thyroid cancers, according to the American Thyroid Association. Because papillary cancer dominates the total, the combined localized and regional figures are close to the papillary figures.

SEER estimates 45,240 new thyroid cancer cases and 2,320 deaths in the United States in 2026. Its death rate is 0.5 per 100,000 people per year, based on 2020 to 2024 deaths.

How do age and AJCC stage change the outlook?

SEER uses three broad groups (localized, regional, distant). Your doctor will more likely give you an AJCC stage from I to IV. The two systems are different, and the American Cancer Society notes that SEER does not group cancers by AJCC stage.

Age is built into the AJCC 8th edition staging for papillary and follicular cancer. A 2018 review of the AJCC 8th edition changes in CA: A Cancer Journal for Clinicians explains the key rules:

Everyone younger than 55 has stage I disease unless the cancer has spread to distant sites. Then it is stage II.
For people 55 or older, distant spread means stage IVB.
For people 55 or older without distant spread, the stage depends on tumor size, lymph node spread, and how far the tumor has grown outside the thyroid.

The American Thyroid Association patient page says the prognosis is excellent, especially for people younger than 55 with a small cancer. It adds that people whose papillary cancer has not spread beyond the thyroid "rarely if ever die from thyroid cancer." For older people or larger, more aggressive tumors, the ATA says the outlook is still very good, but the chance of recurrence is higher.

How can you match these numbers to your own diagnosis?

A survival table only helps if you know which row you belong in. Use your pathology and staging reports, and bring these questions to your care team:

Confirm the type. Check that the report says papillary thyroid carcinoma. Ask if it names a subtype, because some subtypes behave more aggressively. Our guide to thyroid nodule biopsy results explains how the first report is written.
Find the SEER-style stage. Ask if the cancer was confined to the thyroid, had spread to neck lymph nodes, or had spread to distant organs. That tells you which ACS row (localized, regional, or distant) fits you.
Find your AJCC stage. Note your age at diagnosis and whether you were under or over 55. Then ask for the T, N, and M values.
Ask about surgery results. The NCI PDQ patient summary lists whether the cancer was completely removed by surgery as a factor in prognosis. Recovery after the operation is covered in our post on thyroidectomy recovery time.
Ask about recurrence risk. Survival and recurrence are separate questions. Your team may estimate how likely the cancer is to come back, and that guides follow-up and treatments such as radioactive iodine.
Remember the time lag. The ACS says these numbers apply only to the stage at first diagnosis. They are based on people treated at least 5 years ago, so people diagnosed now may do better.

Waiting for staging scans and reports can be stressful. If worry is hard to manage, anxiety.md has plain-language information on scan-related anxiety and how to cope.

What treatment guidelines shape the outlook today?

In August 2025, the American Thyroid Association published the 2025 ATA Management Guidelines for Adult Patients with Differentiated Thyroid Cancer in the journal Thyroid. It updates the earlier guideline, which had combined thyroid nodules and thyroid cancer in one document. The new version covers staging and risk assessment, first treatment decisions, response to treatment, monitoring, and later therapies.

The ATA patient page says thyroid cancer is often cured by surgery alone, especially when it is small. Radioactive iodine may be added when the cancer is larger, has spread to lymph nodes, or carries a higher risk of coming back. If that applies to you, our guide on what to expect after radioactive iodine treatment covers the weeks after a dose.

The NCI PDQ summary also notes that thyroid cancer can come back after treatment, in the neck or in other parts of the body. Long-term follow-up is part of standard care, even when survival odds are excellent.

The bottom line

Papillary thyroid cancer has a 5-year relative survival rate above 99% for all stages combined, per ACS figures from SEER data for 2015 to 2021. Survival is 99% with regional spread and 71% with distant spread. NCI SEER's newer all-types figure of 98.3% (2016 to 2022) groups papillary cancer with rarer, more aggressive types. Your own outlook depends on your age, your AJCC stage, whether surgery removed all the cancer, and your recurrence risk. Ask your care team to place you in the right row of the table.

Last updated: October 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your endocrinologist or cancer care team about your own diagnosis, stage, and prognosis.